CN107693526A - A kind of hypoglycemic oral formulations and preparation method thereof - Google Patents

A kind of hypoglycemic oral formulations and preparation method thereof Download PDF

Info

Publication number
CN107693526A
CN107693526A CN201711088888.9A CN201711088888A CN107693526A CN 107693526 A CN107693526 A CN 107693526A CN 201711088888 A CN201711088888 A CN 201711088888A CN 107693526 A CN107693526 A CN 107693526A
Authority
CN
China
Prior art keywords
parts
irp88
gliclazide
acarbose
oral formulations
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
CN201711088888.9A
Other languages
Chinese (zh)
Inventor
莫玉艳
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority to CN201711088888.9A priority Critical patent/CN107693526A/en
Publication of CN107693526A publication Critical patent/CN107693526A/en
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/64—Sulfonylureas, e.g. glibenclamide, tolbutamide, chlorpropamide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/7036—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin having at least one amino group directly attached to the carbocyclic ring, e.g. streptomycin, gentamycin, amikacin, validamycin, fortimicins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

The invention belongs to pharmaceutical technology field, specifically discloses a kind of hypoglycemic oral formulations and preparation method thereof, by weight fraction meter, is made up of following raw material：5 10 parts of 5 10 parts of gliclazide, 15 20 parts of Metformin hydrochloride, 5 10 parts of acarbose, 10 15 parts of carboxymethyl cellulose, 0.1 0.5 parts of magnesium stearate, 15 parts of polacrilin potassium resin (IRP88), 0.1 0.5 parts of Aspartame and mannitol.The different hypoglycemic drug of several effects is combined by the present invention, has synergy each other, has complementary advantages, improve curative effect, effectively control blood glucose, reduce complication, can also effectively be lost weight while blood glucose is reduced, reduces blood fat etc..

Description

A kind of hypoglycemic oral formulations and preparation method thereof
Technical field
The invention belongs to pharmaceutical technology field, and in particular to a kind of hypoglycemic oral formulations and preparation method thereof.
Background technology
Diabetes (Diabetes Inellitus) are a kind of metabolic diseases of multi-pathogenesis, are characterized in chronic hyperglycemia, It is disorderly with sugar, fat and protein metabolism caused by insulin secretion and/or effect defect.Diabetes can betide any Age, as the course of disease extends, the easily histopathology infringement such as concurrent whole body nerve, capilary and macroangiopathy, and can causing Chronic, the progressive lesion of the histoorgans such as the heart, brain, kidney, nerve and eye, so that final occur blindness, lower limb gangrene, uremic Disease, headstroke or myocardial infarction, or even threat to life.With the improvement of living standards, diabetes turn into a kind of common disease, its The incidence of disease is also increasing year by year.At present, the illness rate of developed country's diabetes is up to 5%-10%, the illness rate in China also oneself Up to 3%.More than 90% is diabetes B in diabetic, and the ability that diabetes B produces insulin in patient body is not complete Complete to lose, some patient's body insulin even produces excessively, but because the Insulin Resistance of body strengthens, and make pancreas islet The action effect unobvious of element, therefore the insulin deficit of patient's body is a kind of relative shortage.
At present, treating the conventional medicine of diabetes has sulfonylureas, biguanides and alpha-glucosidase restrainer, independent medication The defects of different degrees of be present, dosage is big, toxic side effect is obvious etc..Therefore, it is necessary to develop a kind of compound preparation, will act on The different several drugses of mechanism combine, and have complementary advantages, and improve curative effect, effectively control blood glucose, reduce complication.
The content of the invention
In order to solve the above problems, the present invention provides kind of hypoglycemic oral formulations and preparation method thereof, by the mechanism of action Different several drugses combine, and have complementary advantages, and improve curative effect, effectively control blood glucose, reduce complication.
The present invention is only applicable and simple diabetic, there is other diseases or hepatic and kidney function obstacle person disabling.
The technical scheme that the present invention solves above-mentioned technical problem is as follows：A kind of hypoglycemic oral formulations, by weight fraction Meter, is made up of following raw material：Gliclazide 5-10 parts, Metformin hydrochloride 15-20 parts, acarbose 5-10 parts, carboxymethyl are fine Tie up plain 10-15 parts, magnesium stearate 0.1-0.5 parts, polacrilin potassium resin (IRP88) 1-5 parts, Aspartame 0.1-0.5 parts and Mannitol 5-10 parts.
On the basis of above-mentioned technical proposal, the present invention can also do following improvement.
Preferably, a kind of hypoglycemic oral formulations, by weight fraction meter, are made up of following raw material：5 parts of gliclazide, 20 parts of Metformin hydrochloride, 5 parts of acarbose, 15 parts of carboxymethyl cellulose, 0.5 part of magnesium stearate, polacrilin potassium resin (IRP88) 8 parts of 4 parts, 0.2 part of Aspartame and mannitol.
Preferably, a kind of hypoglycemic oral formulations, by weight fraction meter, are made up of following raw material：10 parts of gliclazide, 15 parts of Metformin hydrochloride, 10 parts of acarbose, 10 parts of carboxymethyl cellulose, 0.3 part of magnesium stearate, polacrilin potassium resin (IRP88) 10 parts of 5 parts, 0.1 part of Aspartame and mannitol.
Preferably, a kind of hypoglycemic oral formulations, by weight fraction meter, are made up of following raw material：8 parts of gliclazide, 18 parts of Metformin hydrochloride, 8 parts of acarbose, 12 parts of carboxymethyl cellulose, 0.3 part of magnesium stearate, polacrilin potassium resin (IRP88) 8 parts of 3 parts, 0.5 part of Aspartame and mannitol.
Preferably, a kind of hypoglycemic oral formulations, by weight fraction meter, are made up of following raw material：5 parts of gliclazide, 15 parts of Metformin hydrochloride, 10 parts of acarbose, 10 parts of carboxymethyl cellulose, 0.3 part of magnesium stearate, polacrilin potassium resin (IRP88) 5 parts of 5 parts, 0.1 part of Aspartame and mannitol.
The present invention also provides a kind of preparation method of hypoglycemic oral formulations, concretely comprises the following steps：
Step 1：Gliclazide 5-10 parts, Metformin hydrochloride 15-20 parts, acarbose 5- are taken in pharmaceutical grade clean area 10 parts, carboxymethyl cellulose 10-15 parts, magnesium stearate 0.1-0.5 parts, polacrilin potassium resin (IRP88) 1-5 parts, A Siba Sweet tea 0.1-0.5 parts and mannitol 5-10 parts；
Step 2：It is 1 in mass ratio that melbine, which is weighed, with water:30 ratio mixing, after being completely dissolved it, adds ripple Clarke woods potassium (IRP88) resin carries out ion exchange, reacts 1h, filters washing, and in 60 DEG C of drying, drug containing toner is made, It is standby to cross 80 mesh sieves；
Step 3：By drug containing toner and gliclazide, acarbose, carboxymethyl cellulose, magnesium stearate, A Siba Sweet tea, mannitol are well mixed, tabletting, tablet format 0.25g/ pieces.
Compared with prior art, the beneficial effects of the invention are as follows：
The different hypoglycemic drug of several effects is combined by the present invention, has synergy each other, has complementary advantages, Curative effect is improved, effectively controls blood glucose, complication is reduced, can also effectively be lost weight while blood glucose is reduced, reduces blood fat Deng.
Embodiment
The principles and features of the present invention are described below, and the given examples are served only to explain the present invention, is not intended to limit Determine the scope of the present invention.
Embodiment 1
A kind of preparation of hypoglycemic oral formulations, is concretely comprised the following steps：
Step 1：Gliclazide 5g, Metformin hydrochloride 20g, acarbose 5g, carboxymethyl are taken in pharmaceutical grade clean area Cellulose 15g, magnesium stearate 0.5g, polacrilin potassium resin (IRP88) 4g, Aspartame 0.2g and mannitol 8g；
Step 2：It is 1 in mass ratio that melbine, which is weighed, with water:30 ratio mixing, after being completely dissolved it, adds ripple Clarke woods potassium (IRP88) resin carries out ion exchange, reacts 1h, filters washing, and in 60 DEG C of drying, drug containing toner is made, It is standby to cross 80 mesh sieves；
Step 3：By drug containing toner and gliclazide, acarbose, carboxymethyl cellulose, magnesium stearate, A Siba Sweet tea, mannitol are well mixed, tabletting, tablet format 0.25g/ pieces.
Embodiment 2
A kind of preparation of hypoglycemic oral formulations, is concretely comprised the following steps：
Step 1：Gliclazide 5g, Metformin hydrochloride 20g, acarbose 5g, carboxymethyl are taken in pharmaceutical grade clean area Cellulose 15g, magnesium stearate 0.5g, polacrilin potassium resin (IRP88) 4g, Aspartame 0.2g and mannitol 8g；
Step 2：It is 1 in mass ratio that melbine, which is weighed, with water:30 ratio mixing, after being completely dissolved it, adds ripple Clarke woods potassium (IRP88) resin carries out ion exchange, reacts 1h, filters washing, and in 60 DEG C of drying, drug containing toner is made, It is standby to cross 80 mesh sieves；
Step 3：By drug containing toner and gliclazide, acarbose, carboxymethyl cellulose, magnesium stearate, A Siba Sweet tea, mannitol are well mixed, tabletting, tablet format 0.25g/ pieces.
Embodiment 3
A kind of preparation of hypoglycemic oral formulations, is concretely comprised the following steps：
Step 1：Gliclazide 8g, Metformin hydrochloride 18g, acarbose 8g, carboxymethyl are taken in pharmaceutical grade clean area Cellulose 12g, magnesium stearate 0.3g, polacrilin potassium resin (IRP88) 3g, Aspartame 0.5g and mannitol 8g；
Step 2：It is 1 in mass ratio that melbine, which is weighed, with water:30 ratio mixing, after being completely dissolved it, adds ripple Clarke woods potassium (IRP88) resin carries out ion exchange, reacts 1h, filters washing, and in 60 DEG C of drying, drug containing toner is made, It is standby to cross 80 mesh sieves；
Step 3：By drug containing toner and gliclazide, acarbose, carboxymethyl cellulose, magnesium stearate, A Siba Sweet tea, mannitol are well mixed, tabletting, tablet format 0.25g/ pieces.
Embodiment 4：
A kind of preparation of hypoglycemic oral formulations, is concretely comprised the following steps：
Step 1：Gliclazide 5g, Metformin hydrochloride 15g, acarbose 10g, carboxymethyl are taken in pharmaceutical grade clean area Cellulose 10g, magnesium stearate 0.3g, polacrilin potassium resin (IRP88) 5g, Aspartame 0.1g and mannitol 5g；
Step 2：It is 1 in mass ratio that melbine, which is weighed, with water:30 ratio mixing, after being completely dissolved it, adds ripple Clarke woods potassium (IRP88) resin carries out ion exchange, reacts 1h, filters washing, and in 60 DEG C of drying, drug containing toner is made, It is standby to cross 80 mesh sieves；
Step 3：By drug containing toner and gliclazide, acarbose, carboxymethyl cellulose, magnesium stearate, A Siba Sweet tea, mannitol are well mixed, tabletting, tablet format 0.25g/ pieces.
Comparative example
A kind of preparation of hypoglycemic oral formulations, is concretely comprised the following steps：
Step 1：Taken in pharmaceutical grade clean area Metformin hydrochloride 18g, carboxymethyl cellulose 12g, magnesium stearate 0.3g, Polacrilin potassium resin (IRP88) 3g, Aspartame 0.5g and mannitol 8g；
Step 2：It is 1 in mass ratio that melbine, which is weighed, with water:30 ratio mixing, after being completely dissolved it, adds ripple Clarke woods potassium (IRP88) resin carries out ion exchange, reacts 1h, filters washing, and in 60 DEG C of drying, drug containing toner is made, It is standby to cross 80 mesh sieves；
Step 3：Drug containing toner and carboxymethyl cellulose, magnesium stearate, Aspartame, mannitol are well mixed, Tabletting, tablet format 0.25g/ pieces.
The test of pesticide effectiveness：
The hypoglycemic oral formulations of present invention implementation 1 are used for the clinical test of hyperglycemic patients, evaluate the present embodiment 1 Oral formulations hypoglycemic effect.
1st, case selection：
300 diabetics, wherein male patient 180 are chosen, female patient 120, the oldest is 65 years old, most Small is 38 years old, average age 48 years old, the course of disease -20 years 1 month, is randomly divided into experimental group and control group, every group of 150 people, Huan Zhejun Without Other diseases or medical history, and hepatic and renal function is normal.
2nd, instructions of taking：
Experimental group takes oral formulations made from the embodiment of the present invention 1, three times per day, one at a time, takes before the meal, continuously A week after taking.
Control group takes obtained oral formulations in comparative example of the present invention, three times per day, one at a time, takes before the meal, even Continuous a week after taking
3rd, curative effect judges：
It is effective：Patient blood glucose recovers to normal level；
Effectively, blood glucose level in patients has declined, but to drop to normal level；
Invalid, blood glucose level in patients is without any downward trend.
4th, test result：
The therapeutic effect contrast of hypoglycemic oral formulations is shown in Table in this implementation 1 hypoglycemic oral formulations and comparative example 1, total effective rate 89.3%, inefficiency 10.7%.Specific data are shown in Table 1.
The test result contrast table of table 1
It is effective Effectively It is invalid Total effective rate Inefficiency
Experimental group 78 56 16 89.3% 10.7%
Control group 58 64 28 81.3% 18.6%
In summary, oral formulations hypoglycemic made from the embodiment of the present invention 1 can effectively control blood glucose, therapeutic effect More preferably.

Claims (6)

1. a kind of hypoglycemic oral formulations, it is characterised in that fraction meter by weight, be made up of following raw material：Gliclazide 5- 10 parts, Metformin hydrochloride 15-20 parts, acarbose 5-10 parts, carboxymethyl cellulose 10-15 parts, magnesium stearate 0.1-0.5 Part, polacrilin potassium resin (IRP88) 1-5 parts, Aspartame 0.1-0.5 parts and mannitol 5-10 parts.
A kind of 2. hypoglycemic oral formulations according to claim 1, it is characterised in that fraction meter by weight, by following Raw material forms：5 parts of gliclazide, 20 parts of Metformin hydrochloride, 5 parts of acarbose, 15 parts of carboxymethyl cellulose, magnesium stearate 8 parts of 0.5 part, 4 parts of polacrilin potassium resin (IRP88), 0.2 part of Aspartame and mannitol.
A kind of 3. hypoglycemic oral formulations according to claim 1, it is characterised in that fraction meter by weight, by following Raw material forms：10 parts of gliclazide, 15 parts of Metformin hydrochloride, 10 parts of acarbose, 10 parts of carboxymethyl cellulose, magnesium stearate 10 parts of 0.3 part, 5 parts of polacrilin potassium resin (IRP88), 0.1 part of Aspartame and mannitol.
A kind of 4. hypoglycemic oral formulations according to claim 1, it is characterised in that fraction meter by weight, by following Raw material forms：8 parts of gliclazide, 18 parts of Metformin hydrochloride, 8 parts of acarbose, 12 parts of carboxymethyl cellulose, magnesium stearate 8 parts of 0.3 part, 3 parts of polacrilin potassium resin (IRP88), 0.5 part of Aspartame and mannitol.
A kind of 5. hypoglycemic oral formulations according to claim 1, it is characterised in that fraction meter by weight, by following Raw material forms：5 parts of gliclazide, 15 parts of Metformin hydrochloride, 10 parts of acarbose, 10 parts of carboxymethyl cellulose, magnesium stearate 5 parts of 0.3 part, 5 parts of polacrilin potassium resin (IRP88), 0.1 part of Aspartame and mannitol.
6. a kind of preparation method of hypoglycemic oral formulations, it is characterised in that concretely comprise the following steps：
Step 1：Gliclazide 5-10 parts, Metformin hydrochloride 15-20 parts, acarbose 5-10 are taken in pharmaceutical grade clean area Part, carboxymethyl cellulose 10-15 parts, magnesium stearate 0.1-0.5 parts, polacrilin potassium resin (IRP88) 1-5 parts, Aspartame 0.1-0.5 parts and mannitol 5-10 parts；
Step 2：It is 1 in mass ratio that melbine, which is weighed, with water:30 ratio mixing, after being completely dissolved it, adds Andrea Pollack Woods potassium (IRP88) resin carries out ion exchange, reacts 1h, filters washing, and in 60 DEG C of drying, drug containing toner is made, crosses 80 Mesh sieve is standby；
Step 3：By drug containing toner and gliclazide, acarbose, carboxymethyl cellulose, magnesium stearate, Aspartame, sweet Dew alcohol is well mixed, tabletting, tablet format 0.25g/ pieces.
CN201711088888.9A 2017-11-08 2017-11-08 A kind of hypoglycemic oral formulations and preparation method thereof Withdrawn CN107693526A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201711088888.9A CN107693526A (en) 2017-11-08 2017-11-08 A kind of hypoglycemic oral formulations and preparation method thereof

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN201711088888.9A CN107693526A (en) 2017-11-08 2017-11-08 A kind of hypoglycemic oral formulations and preparation method thereof

Publications (1)

Publication Number Publication Date
CN107693526A true CN107693526A (en) 2018-02-16

Family

ID=61178818

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201711088888.9A Withdrawn CN107693526A (en) 2017-11-08 2017-11-08 A kind of hypoglycemic oral formulations and preparation method thereof

Country Status (1)

Country Link
CN (1) CN107693526A (en)

Similar Documents

Publication Publication Date Title
KR100195886B1 (en) Pharmaceutical composition for treating diabetes mellitus
US20110104290A1 (en) Compositions for reducing blood glucose level and uses thereof
CN101890060B (en) Preparation for nourishing pancreas islet, reducing blood sugar and regulating blood pressure and blood fat and preparation method thereof
CN105267755A (en) Blood-glucose-reducing oral liquid
CN101322761B (en) Medicament for treating tracheitis and bronchitic and preparation thereof
CN104815166B (en) A kind of Chinese medicine composition for treating diabetes and its preparation and application
CN107693555A (en) A kind of medicine and purposes for treating diabetes
CN107898788A (en) A kind of hypoglycemic pharmaceutical composition and preparation method thereof
CN108578419B (en) A kind of hypoglycemic medicine composition of ginsenoside Rg1 and melbine
CN107693526A (en) A kind of hypoglycemic oral formulations and preparation method thereof
CN106214787B (en) A kind of Chinese medicine composition for treating diabetes and preparation method thereof and purposes
CN102836349B (en) Traditional Chinese medicine composition for treating diabetes and preparation method thereof
CN107898795A (en) A kind of hypoglycemic medicine and preparation method thereof
CN100360161C (en) Chinese medicine for treating diabets and nephritis
CN106038668B (en) A kind of medicine for controlling blood sugar concentration
CN107714761A (en) A kind of hypoglycemic medicine and purposes
CN102247515A (en) Traditional Chinese medicine compound preparation used for treating diabetic nephropathy, and preparation method thereof
CN107648288A (en) A kind of hypoglycemic medicine composition and purposes
US6103242A (en) Method of controlling blood sugar levels using Coccoloba uvifera
CN108245625A (en) A kind of hypoglycemic composition and preparation method thereof and purposes
US8703213B2 (en) Anti-diabetic composition containing a plant extract of Englerina lecardii
CN107281408A (en) A kind of hypoglycemic traditional Chinese medicine composition and preparation method thereof
CN101780155A (en) Application of medicament containing liquorice and radix paeoniae alba in preparing synergistic medicament for treating diabetes
CN101036714B (en) Medicinal composition for treating and/or preventing diabetes
Harshamali et al. Evaluation of the effect and efficacy of herbal powder preparation derived from ‘Thalpathe Piliyam’in the management of type II Diabetes mellitus

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
WW01 Invention patent application withdrawn after publication

Application publication date: 20180216

WW01 Invention patent application withdrawn after publication